Chetan Lathia
General Counsel bei BIOXCEL THERAPEUTICS, INC.
Profil
Chetan D.
Lathia is currently the Senior Vice President & Head-Regulatory Affairs at BioXcel Therapeutics, Inc. He previously worked as the Executive Director-Clinical Pharmacology at Alexion Pharmaceuticals, Inc. and as the VP & Head-Clinical Pharmacology at Intarcia Therapeutics, Inc. Lathia holds a doctorate degree from Virginia Commonwealth University and an undergraduate degree from L.
M.
College of Pharmacy.
Aktive Positionen von Chetan Lathia
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOXCEL THERAPEUTICS, INC. | General Counsel | - |
Ehemalige bekannte Positionen von Chetan Lathia
| Unternehmen | Position | Ende |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Ausbildung von Chetan Lathia
| Virginia Commonwealth University | Doctorate Degree |
| L. M. College of Pharmacy | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BIOXCEL THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
